MHRA UK Drug Approval: Post-Brexit Regulatory Framework and Requirements
Since the end of the Brexit transition period on January 1, 2021, MHRA has operated as the UK's medicines regulator outside the EU system. As of January 1, 2024, the main recognition route is the International Recognition Procedure (IRP), and from January 1, 2025 MHRA has regulated medicines through UK-wide marketing authorisations. ILAP remains a separate innovation-support pathway rather than a stand-alone approval route. The standard national assessment procedure targets 210 active assessment days.
Key Takeaways
Key Takeaways
- Post-Brexit, MHRA operates as an independent regulatory authority with its own national licensing procedure for UK marketing authorizations
- The International Recognition Procedure (IRP) is MHRA's current recognition route for certain applications referencing trusted regulators
- The Innovative Licensing and Access Pathway (ILAP) provides an integrated platform for medicines with unmet medical need, combining regulatory and HTA advice
- The Windsor Framework governs medicines regulation in Northern Ireland, maintaining alignment with both UK and EU requirements
- The MHRA regulatory framework has undergone the most significant transformation of any major medicines regulator in recent decades. The UK's departure from the European Union on January 31, 2020, and the end of the transition period on December 31, 2020, severed the UK from the EU's centralized and decentralized regulatory procedures. The Medicines and Healthcare products Regulatory Agency (MHRA) transitioned from operating within the EMA framework to functioning as a fully independent national regulator.
- This guide covers the post-Brexit regulatory landscape as it stands in 2026, including the national route, the International Recognition Procedure, UK-wide licensing, Northern Ireland-specific provisions, and practical considerations for sponsors filing in the UK.
- In this guide, you will learn:
- The MHRA's post-Brexit organizational structure and legal framework
- National marketing authorisation routes available in the UK
- The International Recognition Procedure and reliance pathways
- The Innovative Licensing and Access Pathway (ILAP)
- Northern Ireland Protocol and Windsor Framework implications
- Submission requirements and review timelines
- How the UK framework interacts with EU, FDA, and other regulatory systems
- ---
MHRA: Post-Brexit Organizational Structure
What Is the MHRA?
The Medicines and Healthcare products Regulatory Agency (MHRA) is the UK government agency responsible for regulating medicines, medical devices, and blood components. It is an executive agency of the Department of Health and Social Care (DHSC).
Post-Brexit, the MHRA has assumed full responsibility for functions previously shared with or delegated to the EMA, including:
- Marketing authorisation assessment and approval
- Pharmacovigilance (previously coordinated through EMA's EudraVigilance system)
- Clinical trial authorisation
- GMP inspections
- Batch release (for biologics)
Legal Framework
| Dimension | Details |
|---|---|
| Primary legislation | Human Medicines Regulations 2012 (SI 2012/1916), as amended |
| Governing Act | Medicines Act 1968 (partially superseded by HMR 2012) |
| Post-Brexit amendments | Human Medicines (Amendment etc.) (EU Exit) Regulations 2019 (SI 2019/775) and subsequent amendments |
| Territorial scope | Great Britain (England, Scotland, Wales). Northern Ireland operates under separate provisions. |
The Human Medicines Regulations 2012 (HMR 2012) is the primary secondary legislation governing marketing authorisations. Post-Brexit amendments adapted this legislation to remove references to EU procedures and establish national equivalents.
MHRA Divisions Relevant to Drug Approval
| Division | Function |
|---|---|
| Licensing Division | Assessment and approval of marketing authorisations |
| Safety & Surveillance | Pharmacovigilance, signal detection, risk management |
| Inspectorate | GMP, GCP, GLP, GDP inspections |
| Clinical Trials | Clinical trial authorisation and oversight |
| Innovation Accelerator | ILAP, early access, regulatory advice |
UK Marketing Authorisation: National Licensing Routes
Since January 1, 2021, the UK issues national marketing authorisations (MAs) independent of the EU. There are several routes to obtain a UK MA.
Route 1: National Procedure
The standard national procedure is a full assessment of the marketing authorisation application by MHRA.
| Parameter | Details |
|---|---|
| Applicable products | All product types (new active substances, generics, biologics, etc.) |
| Dossier format | eCTD (electronic Common Technical Document) |
| Assessment type | Full quality, non-clinical, and clinical assessment by MHRA |
| Review target | 210 active assessment days |
| Clock stops | Yes, clock stops for sponsor response to questions |
| Fee | Varies by application type (see MHRA fee schedule) |
The national procedure is conceptually similar to a full NDA/NDS review by FDA or Health Canada, but with UK-specific Module 1 requirements.
Route 2: International Recognition Procedure
The International Recognition Procedure (IRP) allows MHRA to rely in part on assessments conducted by trusted reference regulators when reviewing medicines for the UK.
Eligible reference authorities:
| Authority | Country/Region |
|---|---|
| FDA | United States |
| EMA | European Union (centrally authorised products) |
| Health Canada | Canada |
| TGA | Australia |
| Swissmedic | Switzerland |
| PMDA | Japan (for certain product types) |
How it works:
- The product must be approved (or under review) by one of the eligible reference authorities
- The sponsor submits a UK marketing authorisation application referencing the foreign approval/assessment
- MHRA conducts an abbreviated assessment, relying on the reference authority's review while applying UK-specific considerations
- Review timing depends on the IRP route and the reference authority package; applicants should verify the current route structure and target timelines on the MHRA IRP page before filing
Key conditions:
- UK-specific Module 1 must be prepared (UK labeling, Summary of Product Characteristics in UK format)
- MHRA retains the right to ask additional questions or require additional data
- MHRA makes an independent decision (it may approve, approve with conditions, or refuse even if the reference authority approved)
- Products approved through this route receive a full UK marketing authorisation, not a conditional or provisional one
Route 3: UK-Wide Licensing Context
From January 1, 2025, MHRA has regulated medicines through UK-wide marketing authorisations. The earlier EC Decision Reliance Procedure was a transitional route; sponsors should use current MHRA guidance rather than assume ECDRP remains the operative pathway for new applications.
The Innovative Licensing and Access Pathway (ILAP)
What Is ILAP?
ILAP is the MHRA's flagship innovation pathway, introduced in January 2021. It is designed to accelerate the development and approval of innovative medicines by providing a structured framework for continuous engagement between the sponsor and MHRA.
ILAP is not a separate approval route in the sense of a different review standard. Rather, it is a framework that wraps around the existing approval routes to provide enhanced support, faster timelines, and better coordination.
ILAP Components
| Component | Description |
|---|---|
| Innovation Passport | Initial designation confirming the product is eligible for ILAP. Based on evidence of innovation and unmet medical need. |
| Target Development Profile (TDP) | Collaborative, living document between sponsor and MHRA defining the development plan, regulatory strategy, and evidence requirements |
| Regulatory Toolkit | Access to specific tools: rolling review, conditional MA, accelerated assessment, novel trial designs |
| Multi-agency advice | Coordinated advice from MHRA, NICE (health technology assessment), and NHS England (commercial/access) |
Innovation Passport Criteria
To receive an Innovation Passport, the product must demonstrate:
- Treatment of a serious or life-threatening condition
- Evidence of innovation (new mechanism of action, significant improvement over existing therapies, or platform technology)
- Potential for significant patient benefit
- Plausible clinical development plan
Target Development Profile (TDP)
The TDP is one of the most novel aspects of ILAP. It is a jointly developed document that outlines:
- Agreed regulatory requirements for approval
- Clinical development strategy
- Health technology assessment data needs (coordinated with NICE)
- Commercial access considerations (coordinated with NHS England)
The TDP is a living document that is updated as development progresses. It reduces uncertainty about what data MHRA (and NICE) will require, enabling more efficient development programs.
ILAP Review Timelines
Products in ILAP may benefit from:
- Rolling review: Submit sections of the dossier as they become available
- Accelerated assessment: Reduced review target (approximately 150 days vs. 210 for standard)
- Conditional marketing authorisation: Approval based on less complete data with post-approval confirmatory study requirements
Northern Ireland: The Windsor Framework
Background
Under the Northern Ireland Protocol (initially agreed in 2019, revised by the Windsor Framework in 2023), Northern Ireland (NI) remains aligned with EU pharmaceutical regulations for certain purposes. This creates a unique dual-regulatory situation within the UK.
Medicines Regulation in Northern Ireland
| Dimension | Northern Ireland | Great Britain |
|---|---|---|
| Regulatory framework | EU pharmaceutical directives and regulations apply | UK Human Medicines Regulations 2012 (as amended) |
| Marketing authorisation | UK-wide MA, with specific NI rules still relevant in some procedural contexts | UK-wide MA, national procedure, IRP |
| Labeling | Must comply with EU labeling requirements | UK labeling requirements |
| Pharmacovigilance | EU pharmacovigilance system (EudraVigilance) and UK system | UK pharmacovigilance system (Yellow Card) |
| Batch release | EU Qualified Person release requirements | UK Qualified Person release requirements |
Windsor Framework Medicines Provisions
The Windsor Framework and related 2024 legislation changed medicines regulation substantially:
- UK-wide licensing from January 1, 2025: MHRA now issues UK-wide marketing authorisations for human medicines
- Reduced divergence for NI supply: the framework was designed to maintain supply continuity while moving away from the earlier GB-versus-NI split
- Labeling flexibilities: Reduced labeling requirements for products moving from GB to NI
- Supply continuity: Provisions to ensure that medicines available in GB continue to be available in NI
These provisions are being implemented in phases. The practical effect is to reduce the regulatory burden for sponsors wishing to supply the entire UK market, while maintaining EU standards in NI for products moving into the EU single market.
Submission Requirements for UK Marketing Authorisation
eCTD Format
MHRA requires eCTD format for all marketing authorisation applications. The eCTD follows the ICH CTD structure with UK-specific Module 1 content.
UK Module 1 Requirements
| Section | Content |
|---|---|
| 1.1 | Table of Contents |
| 1.2 | Application form (MHRA online application) |
| 1.3 | Summary of Product Characteristics (SmPC), Patient Information Leaflet (PIL), Labeling |
| 1.4 | Mock-ups and samples of labeling |
| 1.5 | Expert reports (quality, non-clinical, clinical) |
| 1.6 | Environmental risk assessment |
| 1.7 | Orphan drug designation (if applicable) |
| 1.8 | Pharmacovigilance system details |
| 1.9 | Risk Management Plan |
Summary of Product Characteristics (SmPC)
The UK SmPC follows a format derived from the EU SmPC template but with UK-specific modifications post-Brexit:
- Format: Follows QRD (Quality Review of Documents) template as adapted for UK use
- Content: Therapeutic indications, posology, contraindications, special warnings, interactions, fertility/pregnancy/lactation, effects on driving, undesirable effects, overdose, pharmacological properties, pharmaceutical particulars
- Language: English (no bilingual requirement)
- UK-specific elements: Reference to UK clinical practice, NHS formulary considerations where relevant
Patient Information Leaflet (PIL)
The PIL must be provided in English and follow the UK format requirements. The PIL must be user-tested per MHRA guidance to ensure readability and comprehension.
Risk Management Plan (RMP)
MHRA requires an RMP following the EU-RMP format (adapted for UK use). The RMP includes:
- Safety specification
- Pharmacovigilance plan (routine and additional activities)
- Risk minimisation measures
- Post-authorisation safety studies (if applicable)
Review Timelines
Assessment Timeframes by Route
| Route | Target (active assessment days) | Notes |
|---|---|---|
| National Procedure (full) | 210 days | Plus clock-stop time for sponsor responses |
| International Recognition Procedure | Verify current route-specific timeline on MHRA guidance | Depends on IRP route and reference package |
| ILAP (accelerated) | 150 days | For Innovation Passport holders |
| Generic/Abridged | 210 days | Standard abridged application |
Fee Structure
MHRA fees are published annually in the MHRA fee schedule. Approximate fees (as of recent fee schedules):
| Application Type | Fee (GBP, approximate) |
|---|---|
| National MA (new active substance) | 115,000 - 140,000 |
| National MA (generic/abridged) | 30,000 - 40,000 |
| International Recognition route | Reduced fee (varies) |
| Type II variation (clinical) | 25,000 - 50,000 |
| Annual maintenance fee | 3,000 - 5,000 |
Fees are subject to annual revision. Verify current fees on the MHRA website before filing.
Post-Brexit Regulatory Reforms: Great British Life Sciences
Overview
The UK government has used regulatory sovereignty post-Brexit to implement reforms aimed at making the UK an attractive destination for pharmaceutical investment and clinical trials. Key initiatives include:
Faster access to medicines: MHRA has set an ambition to be a consistently first-in-class regulator, approving innovative medicines at least as fast as FDA and EMA.
Regulatory sandbox: MHRA has explored sandbox approaches for novel product types (ATMPs, AI-enabled diagnostics, point-of-care manufacturing).
Clinical trials reform: The Medicines and Healthcare Products Regulatory Agency (Amendment Relating to Clinical Trials) Regulations replaced the EU Clinical Trials Directive framework with a UK-specific clinical trials framework, aiming to reduce bureaucracy and speed up trial approvals.
International partnerships: Beyond the International Recognition Procedure, MHRA has established bilateral agreements and information-sharing arrangements with FDA, Health Canada, TGA, and other regulators as part of evolving global regulatory strategy approaches. MHRA is also a member of the Access Consortium (formerly ACSS, originally comprising Australia, Canada, Singapore, and Switzerland, with MHRA joining post-Brexit) alongside Health Canada, TGA, Swissmedic, and HSA Singapore.
Access Consortium
The Access Consortium enables work-sharing between MHRA and partner agencies:
| Partner | Country |
|---|---|
| Health Canada | Canada |
| TGA | Australia |
| Swissmedic | Switzerland |
| HSA | Singapore |
Work-sharing allows one agency to take the lead on assessment while others rely on the lead assessor's report, adapted for national requirements. This reduces duplication and can accelerate approval across multiple markets.
Practical Considerations for Sponsors
Filing Strategy for the UK Post-Brexit
| Scenario | Recommended Route |
|---|---|
| Product already approved by FDA, EMA, or another eligible reference regulator | International Recognition Procedure |
| Product under review at FDA or EMA | International Recognition (parallel review) |
| Novel product with UK-first strategy | ILAP + National Procedure |
| Generic product | National Procedure (abridged application) |
| Product for entire UK (including NI) | National Procedure with Windsor Framework provisions |
Common Filing Mistakes
| Mistake | Consequence | Prevention |
|---|---|---|
| Using EU SmPC without UK adaptation | Rejection/query | Prepare UK-specific SmPC using UK QRD template |
| Missing UK Qualified Person | Processing delay | Identify UK QP for batch release before filing |
| Referencing EU-only data sources | Assessment query | Ensure all data references are accessible to MHRA |
| Ignoring NI requirements | Inability to supply NI | Plan NI supply strategy early, considering Windsor Framework |
| Not engaging ILAP for innovative products | Missed opportunity for faster review | Apply for Innovation Passport early in development |
Brexit severed the UK from the EU's regulatory framework, requiring MHRA to operate as an independent regulator. The UK can no longer participate in EU Centralised, Decentralised, or Mutual Recognition Procedures as a member state. Instead, MHRA uses UK national procedures, the International Recognition Procedure, and UK-wide licensing arrangements. Products previously authorised through EU routes were addressed through transitional conversion and subsequent UK-wide licensing changes.
Key Regulatory References
- Human Medicines Regulations 2012 (SI 2012/1916), as amended
- Human Medicines (Amendment etc.) (EU Exit) Regulations 2019 (SI 2019/775)
- MHRA Guidance: Routes to marketing authorisation
- MHRA Guidance: International Recognition Procedure
- MHRA Guidance: Innovative Licensing and Access Pathway (ILAP)
- MHRA Guidance: UK-wide licensing for human medicines
- Windsor Framework: Medicines provisions
- UK Internal Market Act 2020
- MHRA Fee Schedule (current version on MHRA website)
This guide reflects the UK regulatory framework as of early 2026. The post-Brexit regulatory landscape continues to evolve as MHRA implements reforms and refines pathways. Always verify current requirements on the MHRA website (www.gov.uk/mhra) before filing.